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Abstract 
Background: As the prognosis of women with prosthetic heart valves improves more of these 
individuals are contemplating and undertaking pregnancy.  Accurate knowledge of perinatal 
outcomes is essential, assisting counselling and guiding care.  The aim of this study was to 
assess outcomes in a contemporary population of women with heart valve prostheses 
undertaking pregnancy, and to compare outcomes for women with mechanical and 
bioprosthetic prostheses. 
Method and results: Longitudinally-linked population health datasets containing birth and 
hospital admissions data were obtained for all women giving birth in New South Wales, 
Australia, 2000-2011. This included information identifying presence of maternal prosthetic 
heart valve.  Cardiovascular and birth outcomes were evaluated.  Among 1 144 156 
pregnancies, 136 involved women with a heart valve prosthesis (1 in 10 000).  No maternal 
mortality was seen among these women, although the relative risk for an adverse event was 
higher than the general population, including severe maternal morbidity (13.9% v. 1.4%, 
RR=9.96, 95% CI 6.32-15.7), major maternal cardiovascular event (4.4% v. 0.1%, RR 34.6, 
95% CI 14.6-81.6), preterm birth (18.3% v. 6.6%, RR=2.77, 95% CI 1.88-4.07) and small-
for-gestational-age infants (19.3% v. 9.5%, RR=2.12, 95% CI 1.47-3.06).  There was a trend 
towards increased maternal and perinatal morbidity in women with a mechanical valve 
compared to bioprosthetic. 
Conclusions: Pregnancies in women with a prosthetic heart valve demonstrate an increased 
risk of an adverse outcome, for both mothers and babies, compared with pregnancies in the 
absence of heart valve prostheses.  In this contemporary population, the risk was lower than 
previously reported. 
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Introduction 
With advances in surgical technique, prosthetic heart valve design and anticoagulation there 
has been an overall improvement in prognosis and quality of life of young women with a 
prosthetic heart valve 1-4.  There still remains a paucity of data in regards to the maternal, fetal 
and infant outcomes of the pregnancies of these women. 
Normal pregnancy is a procoagulant state 5, 6 in which the body experiences an increased 
haemodynamic load 7-9.  Tolerance of these changes by women with pre-existing heart disease 
during pregnancy is known to vary 10.  With gradual improvements in risk stratification and 
understanding of what conditions and cardiac parameters drive high risk during pregnancy, 
the number of these women counselled explicitly against pregnancy is decreasing 10, 11.  
Current knowledge of pregnancy outcomes for women with a previous heart valve prosthesis 
implantation remains limited.  Previous research on the outcomes of pregnancies in these 
women reflects a population of women with largely older, more thrombogenic mechanical 
valves and focuses on anticoagulation regimen 12-17.  There is a need to examine pregnancy 
outcomes in a contemporary population, particularly given the increasing number of 
bioprosthetic valves implanted in women wishing to bear children, in accordance with 
international guidelines which advocate the consideration of this 11, 18, 19. 
Improvement in care for chronic and congenital cardiac disease as well as the delayed age of 
childbearing is expected to contribute to an increase in the number of women with heart valve 
prostheses experiencing pregnancy.  Routinely collected birth and hospital data represent an 
important resource for identifying women experiencing pregnancy with an existing heart 
valve prosthesis and provides data useful for exploring rare conditions, interventions and 
subsequent health outcomes.  Contemporary knowledge is vital in assisting pre-pregnancy 
counselling and guiding care for women with heart valve prostheses and their offspring 
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during pregnancy and beyond.  The aim of this study therefore was to assess the 
cardiovascular and birth outcomes of a contemporary population of women with a heart valve 
prosthesis undertaking pregnancy, and to compare outcomes for women with mechanical and 
bioprosthetic valves. 
Methods 
The study population included all women giving birth in New South Wales (NSW), Australia 
between 2000 and 2011.  New South Wales (NSW) is Australia’s most populous state with 
over 7 million residents (32% of the Australian population) and 95,000 births per annum 20. 
Data were obtained from two routinely collected population datasets, the NSW Perinatal Data 
Collection (PDC) and NSW Admitted Patient Data Collection (APDC).  The PDC, referred to 
as ‘birth records’, is a population-based surveillance system of all births (including all live 
births and stillbirths of at least 20 weeks gestation or 400 grams in weight).  The APDC, 
referred to as ‘hospital records’, is an administrative database of all public and private 
hospital admissions.  It includes 20 or more diagnoses and procedures for each hospital 
admission, coded according to the International Classification of Diseases Australian 
Modification (ICD10-AM) and the Australian Classification of Health Interventions.  Record 
linkage of the PDC and APDC (including mothers’ and infants’ hospital admissions for the 
birth) and longitudinal linkage of hospitalisations up to 10 years prior to birth and 6 weeks 
postpartum) was undertaken by the NSW Centre for Health Record Linkage.  As Australia 
does not have a unique registration number for citizens, the separate datasets were linked 
using probabilistic linkage methods and a best practice approach in preserving privacy 21, 22.  
This involves a process of blocking and matching combinations of selected variables such as 
name, date of birth, address and hospital and assigning a probability weight to the match.  
The validity of the probabilistic record linkage is extremely high 23.  For this study, quality 
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assurance assessments reported false positive and negative rates of 0.3% and <0.5% 
respectively.  Over 98% of birth records linked to a mother’s hospital record.  The study was 
approved by the NSW Population and Health Services Research Ethics Committee (Approval 
number: 2012/12/430). 
Hospital records were used to identify women who had heart valve prosthesis implanted prior 
to the time of giving birth.  Separate procedure codes for heart valve prosthesis implantation 
surgery by valve location and type of prosthesis exist.  Women who had a heart valve 
prosthesis implanted prior to 2000 could be identified only by a ICD 10 AM diagnostic code 
indicating an extant prosthesis (Z95.2, Z95.3, T82.0) in the pregnancy/delivery hospital 
records, with no specification of valve type or location.  After 2000, valve location and type 
of prosthesis was identifiable.  Diagnoses of valvular disease and other maternal medical 
conditions, as well as cardiovascular outcomes, were also obtained from the hospital records; 
this information was not documented in the birth records.  Valvular disease aetiology was 
obtained taken from any admission record with the relevant code, before or after valve 
replacement, or during pregnancy. 
Maternal cardiovascular outcomes evaluated included stroke, myocardial infarction, heart 
failure, a new arrhythmia and endocarditis.  Other vascular outcomes evaluated included new 
pulmonary embolism or other severe thromboembolic events.  A composite outcome for any 
major cardiovascular event was used (stroke, myocardial infarction, heart failure, 
thromboembolic event and endocarditis) during pregnancy or up to 42 days postpartum.  
Severe maternal morbidity during the birth admission was measured using a validated 
composite outcome indicator that was developed specifically for use in routinely collected 
population health data 24. 
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The hospital and birth records provided maternal characteristics (age, country of birth, 
medical conditions), while birth records provided pregnancy characteristics (parity, induction 
of labour, mode of delivery, place of birth) and birth outcomes (gestational age, birthweight, 
perinatal death) for women who had a birth ≥20 weeks gestation. The birth record was also a 
supplemental source to identify women who suffered chronic hypertension, pregnancy 
hypertension (including gestational hypertension, preeclampsia and eclampsia) and diabetes 
(pre-existing and gestational).  Only miscarriages (spontaneous abortion before 20 weeks 
gestation) that resulted in admission to hospital were identifiable from hospital records.  
Stillbirth was defined as fetal death of at least 20 weeks gestation or 400 grams birthweight.  
Neonatal death was defined as death of a live born infant during the first 28 days of life.  
Perinatal death included all stillbirths and neonatal deaths.  Small for gestational age (SGA), 
a proxy for intrauterine growth restriction, was defined as <10th birthweight percentile for 
gestational age and infant sex 25.  Maternal length of stay and intensive care unit (ICU) 
admission during the birth hospitalisation (to discharge home) were obtained from the 
hospital data.  Only pregnancy outcomes reliably reported in the population health data were 
included in the analyses 24, 26-28.  Information on medication use during pregnancy (i.e. use of 
oral anticoagulant or heparin) was not available on either dataset.   No pregnancy or birth 
outcome information was missing for women with a heart valve prosthesis. 
For the analysis of miscarriage and maternal characteristics, the study denominator was all 
pregnancies, including miscarriage.  The analysis of delivery and birth outcomes was 
restricted to births ≥20 weeks gestation, for which outcomes such as SGA and perinatal death 
could be assessed.  Admission summaries for women experiencing a miscarriage were also 
searched for diagnoses of major cardiovascular events, but none of the miscarriages in the 
study population were associated with such an event.  The rates of birth outcomes for women 
with and without a prosthetic heart valve prosthesis (and mechanical versus bioprosthetic 
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valve type) were compared using contingency table analysis and by calculating rate ratios 
(RR) with 95% confidence intervals (CI). The comparisons of outcomes for women with 
mechanical prostheses versus bioprosthetic valves were similarly performed using 
contingency table analyses, as for almost all outcomes there were too few events to support a 
multivariable adjusted analysis. 
Results 
From 2000 to 2011, 87 women with heart valve prostheses experienced a total of 136 
pregnancies.  The prevalence of heart valve prostheses among the pregnant population was 
approximately 1 per 10,000 pregnancies (136/1 144 156).  Baseline characteristics of the 
pregnancies with and without heart valve prostheses are shown in Table 1.  
Thirty-five women had an admission record for their valve implantation procedure; this group 
experienced 58 pregnancies subsequent to this surgery.  The average age at time of surgery 
for these women was 26.0 years (standard deviation ±6.2 years) and the mean interval 
between surgery and subsequent birth was 2.3 years (range 0.7 to 8.8 years).  The remaining 
52 women with a code identifying the presence of a heart valve prosthesis did not have an 
admission record for the valve insertion procedure, performed prior to 2000.  The age of 
these 52 women as of 2000 ranged from 11 to 36 years, with a median age of 25 years.  This 
group experienced 78 pregnancies during the study period.  With the exception of four 
women (with six pregnancies) who had a diagnostic code indicating a xenograft valve, the 
valve prosthesis type and age at insertion in these women with pre-2000 valve prosthesis 
insertion was unknown. Combined with the four women identified as having a pre-2000 
xenograft, the valve type (mechanical or bioprosthetic) was known for a total of 39 women 
experiencing 64 pregnancies.  Valvular disease aetiology could be ascertained for 75 (55%) 
pregnancies, and of these 26 (19%) were attributed to rheumatic heart disease. 
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Of women with a known bioprosthetic valve, 46% experienced more than one pregnancy, as 
opposed to only 29% of those with a mechanical prosthesis.   No pregnancies with prosthetic 
valves were complicated by pre-existing diabetes, but 13 were complicated by chronic 
hypertension. 
Twenty-one women with a heart valve prosthesis were hospitalised with a miscarriage, 19 
before 14 weeks gestation and two in the 14-19 gestational week category.  A hospital 
admission with miscarriage was more frequent among women with valve prostheses than 
those without (15.4% versus 9.3%, RR=1.65, 95% CI 1.12-2.45), and among those with 
mechanical valves compared with bioprosthetic valves although this latter difference did not 
reach statistical significance (30% versus 14%, RR=2.20, 95% CI 0.81-5.98).  For the 21 
pregnancies ending in miscarriage with an associated hospital admission, no major 
cardiovascular events were identified, although one woman was diagnosed with a 
supraventricular tachycardia.  Miscarriages not associated with a hospital admission were 
unable to be identified in women with or without prostheses. 
Pregnancy outcomes for births ≥20 weeks gestation, with and without a prosthetic valve, are 
reported in Table 2.  Compared with births where the mother did not have a prosthetic heart 
valve (n=1 144 020), those with valve prostheses (n=136) were more likely to have a hospital 
admission for arrhythmia (5.2% versus 0.3%, RR=16.0, 95% CI 7.35-35.0), have their 
pregnancy care in a tertiary centre (71.3% versus 44.7%, RR=1.60, 95% CI 1.42-1.79) and be 
admitted to intensive care during the birth admission (6.1% versus 0.8%, RR=7.34, 95% CI 
3.58-15.1).  One of the admissions for arrhythmia was an antenatal admission, the other five 
were at birth or postpartum.  Of the arrhythmias documented, five were atrial fibrillation; one 
was non-specifically labelled as “tachycardia”.  Only five women with prosthetic valves 
suffered a major cardiovascular event. None of the women with a prosthetic heart valve were 
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diagnosed with endocarditis during pregnancy or the postpartum period.  Women with a 
valve prosthesis were significantly more likely to have a preterm delivery (18.3% versus 
6.6%, RR=2.77, 95% CI 1.88-4.07). These preterm deliveries were most commonly 
iatrogenic; by planned pre-labour caesarean section or induction of labour (12.2% versus 
2.8%, RR=4.37, 95% CI 2.68-7.14). Overall, infants of mothers with a heart valve prosthesis 
had an increased rate of SGA (19.3% versus 9.5%, RR= 2.12, 95% CI 1.47-3.06). 
Birth outcomes by mechanical versus bioprosthetic valve type, for the 52 births where valve 
type was known, are shown in Table 3. Numbers were small, with only incidence of 
caesarean section delivery and planned births (by labour induction or pre-labour caesarean) 
reaching statistical significance, which was higher in the group with a mechanical prosthesis.  
The point estimates of risk for preterm birth, postpartum haemorrhage, ICU admission and 
severe maternal morbidity were all higher for mechanical valve pregnancy.  The rate of major 
CV events was roughly comparable between women with mechanical versus bioprosthetic 
valve, although a major cerebrovascular accident attribute to thrombosis was seen in one 
woman with a mechanical valve.  The three events among women with bioprosthetic valves 
were all admissions due to congestive heart failure.  
Discussion 
From this large, contemporary, population-based study, pregnancies in women with a 
prosthetic heart valve demonstrate an increased incidence of adverse outcomes, for both 
mothers and babies, when compared with pregnancies in women without a prosthetic heart 
valve.  Women with a prosthetic heart valve are at an increased risk of ICU admission, severe 
maternal morbidity or a major maternal cardiovascular event during pregnancy.  Their babies 
are at an increased risk of preterm birth and small for gestational age.  However, the 
frequency and rate ratios for these adverse outcomes were lower than previously reported in 
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population studies 29, 30 and a systematic review of women with mechanical heart valve 
prostheses only 17. 
A previous systematic review of outcomes of women with heart valve prostheses undertaking 
pregnancy, focusing on impact of anticoagulation regimen, found maternal mortality 
complicated 2.9% (95% CI 1.9-4.2) of pregnancies in women with a mechanical heart valve 
prosthesis.  A higher prevalence of other adverse events in these pregnancies was also 
reported, including major bleeding (2.5%, 95% CI 1.7-3.5) and thromboembolic events 
(3.9%-33.3%, dependent on anticoagulant regimen) 17.  While still demonstrating a higher 
incidence of perinatal mortality than among women without a heart valve prosthesis, 
complications in this NSW population were much fewer, with no maternal mortality seen.  
This likely reflects the contemporary population of valve recipients; with less of the more 
thrombogenic cage-and-ball style valves, accounting for 49.7% of the valves in women in the 
previous systematic review, as well as the presence of bioprosthetic valve recipients.  In 
addition to the higher rate of thromboembolic events, the higher level of anticoagulation 
required for cage-and-ball valves is associated with an increased incidence of haemorrhagic 
events and fetal demise 17.  Based on the use of cage-and-ball valves over time in Australia 31, 
32, and the maternal age of the study population, we estimate that no more than 3 of the 136 
(2.2%) pregnancies in this study are likely to have occurred in the context of these valves.   
The choice of valve prosthesis type in women of reproductive age remains at the discretion of 
the physician and woman.  International guidelines recommend that bioprosthetic valves be 
considered in women wishing to undertake pregnancy in the future to avoid the complications 
associated with anticoagulation required for mechanical valves 11, 18, 19.  Current evidence 
suggests that there is no increase in deterioration of bioprosthetic valves during pregnancy 33-
35 although there is a noted propensity for earlier valvular dysfunction with bioprosthetic 
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valves as opposed to mechanical valves, with implications for re-operation 36.  From the 
population data evaluated in this study there was a trend towards mechanical valve 
association with higher relative risk of ICU admission, cardiac events, PPH and stillbirth, 
when compared to bioprosthetic valves.  Despite having 10 years of longitudinally linked 
birth data, a longer time frame may be needed to have sufficient number of birth outcomes by 
valve type to draw conclusions about relative birth outcomes. 
Recently published studies which examine contemporary pregnancies in the setting of 
maternal mechanical or bioprosthetic heart valves include only small numbers of women with 
bioprosthetic heart valves, precluding subgroup analysis 30, 37, 38.  Larger studies focusing 
solely on pregnancies in those women with a bioprosthetic heart valve contain scant 
information on pregnancy and infant outcomes 33, 34, 39.  The cohort presented in this study, 
containing 38 pregnancies in which the woman was known to have a bioprosthetic heart 
valve, represents the largest published series examining maternal, fetal and infant outcomes 
in women with this type of prostheses with all pregnancies occurring in the contemporary 
setting (after 2000). 
The propensity for development of congestive heart failure, seen in 8% of the women with a 
bioprosthetic valve and in previous studies 40-42, supports the need for a structured regimen of 
cardiac surveillance during pregnancy.  There has been limited work advocating the role of 
serial B-type natriuretic peptide (BNP) measurements in predicting cardiovascular adverse 
events in pregnancy 43, not yet explored in the prosthesis setting.  BNP has also been shown 
as a measure of valvular disease severity outside the pregnancy setting 44.  Further work in 
this area may allow women to be better informed about the risks of undertaking pregnancy 
and guide both obstetricians and cardiologists.   
Infants born to women with a heart valve prosthesis in this study had an increased incidence 
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of preterm birth as well as SGA.  Of the 21 preterm births, 14 were iatrogenic (12.2% versus 
2.8%, RR 4.37, 95% CI 2.68-7.14).  In a large, population-based Danish study prematurity 
was also the predominant adverse neonatal event, affecting 49% of live births.  This was 
similarly iatrogenic, attributable to a high preterm caesarean section rate 30.  This method of 
delivery allows control of the anticoagulation regimen and decreases the risk of intracerebral 
haemorrhage associated with vaginal delivery of an anticoagulated fetus.  SGA infants may 
also have been delivered electively pre-term due to concerns about intrauterine growth 
restriction or other fetal compromise, potentially contributing to the number of iatrogenic 
preterm births.  The risk for extreme prematurity (gestational age 20-27 weeks), carrying the 
most significant morbidity, of infants born to mothers with a heart valve prosthesis in the 
NSW population was small (2.6%), although not insignificant. 
The higher incidence of SGA infants seen has been noted in previous cohort studies 
examining populations of women with heart disease undertaking pregnancy 10, 45, 46 and 
specifically in pregnancy in the setting of heart valve prostheses 40, 42, 47.  A number of reasons 
have been proposed to account for this.  Firstly, the potential inability of women with a 
degree of cardiac insufficiency to increase requirements sufficient for normal fetal growth, as 
postulated in studies where having a SGA infant was used to predict later maternal 
cardiovascular mortality in healthy women 48.  Or secondly, as a reflection of the poorer 
health status in general of women with chronic heart disease 46.  There has been limited work 
examining the longitudinal outcomes of infants born to a woman with a heart valve 
prosthesis, a potentially important area of further research given the increase in number of 
women with any heart disease undertaking pregnancy. 
The strengths of this study include the size of the population evaluated, representing one of 
the largest reported series of pregnancies in contemporary heart valve recipients.  This study 
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also provides the most comprehensive consideration of cardiac and perinatal outcomes in 
pregnancies subsequent to 2000 where a maternal bioprosthetic heart valve is present.  
Another strength is the known reliability of the reporting of the perinatal factors in the PDC, 
used in this study 26, 27.  While the validity of the identification of valve prostheses in routinely 
collected data has not been evaluated, other cardiac procedures (for example, angioplasty and 
coronary artery bypass grafting), the basis for billing, are reliably and accurately reported 49. 
The high quality of the record linkage for the study highlights the value of record linkage in 
exploring rare conditions, interventions and subsequent health outcomes, with all women 
experiencing ongoing pregnancies in NSW and outcomes included. 
While this study explores the pregnancy and birth outcomes for women with and without an 
existing prosthetic heart valve it is unable to answer whether women with a prosthetic heart 
valve are less likely or unable to experience pregnancy.  Other limitations include a lack of 
detailed clinical information; data on medication use or the temporality of events during an 
admission was unavailable.  Information on specific heart valve type (mechanical or 
bioprosthetic) for some women undergoing valve prosthesis implantation prior to 2000 was 
also unavailable, contributing to an incomplete profile for these pregnancies.  There is also 
under-ascertainment of miscarriages and terminations of pregnancy in both women with heart 
valve prostheses and the wider population as this is only available if there is an associated 
hospital admission. 
Conclusion 
Pregnancies in women with a heart valve prosthesis, even in the contemporary setting, still 
demonstrate a higher incidence of adverse cardiovascular and pregnancy outcomes.  The risk 
of these is relatively low and no maternal mortality was seen in this population.  While this 
contemporary data supports that bioprosthetic valves are safer during pregnancy, larger 
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numbers of women are needed to confirm this as well as longer follow-up of valve related 
complications and childhood outcomes.  Ongoing attention in this area is needed for the 
development of a structured, multidisciplinary regimen for obstetric and cardiac surveillance 
during pregnancy in women with a heart valve prosthesis.  
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Table 1. Pregnancy characteristics by maternal prosthetic heart valve status for all 
pregnancies*  
Pregnancy 
characteristics 
Any 
prosthetic 
valve N=136 
(87 women) 
Mechanical 
valve 
N=20  
(14 women) 
Bioprosthetic 
valve  
N=44  
(25 women) 
Valve 
prosthesis 
type 
unknown 
N=72 
(48 women) 
No valve 
prosthesis 
N=1,144.020 
(651,072 
women) 
 
Maternal age 
(mean± 
standard 
deviation) 
30.2 (5.6) 29.5 (7.4) 29.8 (4.5) 30.7 (5.7) 30.5 (5.7) 
 n (%) n (%) n (%) n (%) % 
Nulliparous 48 (35)   9 (45) 12 (27) 27 (38) 42.1 
Maternal birth 
in Australia/NZ 
101 (74) 13 (65) 35 (80) 53 (74) 68.4 
      
Valve disease 
aetiology 
     
Rheumatic 
heart disease 
26 (19)   6 (30) 8 (18) 12 (17) 0.06 
Non-
rheumatic 
49 (36) 12 (60) 25 (57) 12 (17) 0.21 
Not recorded 61 (45) 2 (11) 11 (25) 48 (67) ─ 
      
Valve 
prosthesis 
location 
     
Mitral 21† (15) 10 (50) 11† (25) NA ─ 
Aortic 15† (11)   6 (30)   9† (20) NA ─ 
Tricuspid or 
pulmonary 
23 (17)   4 (20) 19 (42) NA ─ 
Not recorded 78 (57)   0 (0)   6 (14) 72 (100) ─ 
      
Miscarriage 
admission 
21 (15) 6 (30) 6 (14) 9 (13) 9.0 
 
* Includes pregnancies ending in live birth, stillbirth or hospital admission for miscarriage 
† One woman had both a mitral and aortic bioprosthesis at the time of pregnancy 
NA not available, NZ New Zealand 
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Table 2. Pregnancy outcomes, by prosthetic heart valve status (all births ≥ 20 weeks) 
 Pregnancy outcome Valve 
prosthesis 
N=115 
n (%) 
No valve 
prosthesis 
N=1,037,159 
% 
Rate ratio* 
RR (95% CI) 
Pregnancy hypertension  17 (14.8) 9.5 1.67 (1.08-2.59) 
Gestational diabetes 2 (1.7) 4.7 0.30 (0.08-1.17) 
Induction of labour  32 (27.8) 25.2 1.10 (0.82-1.48) 
Caesarean section    
Pre-labour  38 (33.0) 16.1 2.06 (1.59-2.67) 
Intrapartum  14 (12.2) 11.9 1.02 (0.63-1.67) 
Gestational age    
20-27 weeks 3 (2.6) 0.7 3.94 (1.29-12.0) 
28-33 weeks 6 (5.2) 1.4 3.72 (1.71-8.11) 
34-36 weeks 12 (10.4) 4.5 2.31 (1.35-3.95) 
37-38 weeks 41 (35.7) 22.1 1.61 (1.26-2.06) 
≥ 39 weeks 53 (46.1) 71.3 0.64 (0.53-0.78) 
Planned preterm birth† 14 (12.2) 2.8 4.37 (2.68-7.14) 
Perinatal death 2 (1.7) 0.9 1.96 (0.50-7.73) 
SGA infant‡ 22 (19.3) 9.5 2.12 (1.47-3.06) 
Birth admission 
    Severe maternal morbidity 
    Length of admission (days: median, IQR) 
    ICU admission 
    Postpartum haemorrhage 
 
16 (13.9) 
4 (3-7) 
 7 (6.3) 
17 (14.8) 
 
1.4 
4 (2-5) 
0.8 
7.1 
 
9.96 (6.32-15.7) 
 
7.34 (3.58-15.1) 
2.09 (1.35-3.24) 
Major maternal cardiovascular event to 42 
days postpartum 
5 (4.4) 0.1 34.6 (14.6-81.6) 
    
* Rate ratio of each outcome among births where the mother had a prosthetic heart valve compared to 
those who did not have a prosthetic valve 
† Induction of labour or pre-labour caesarean section at <37 weeks 
‡ Denominator for SGA infant is all births >24 weeks, n=114
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Table 3. Pregnancy outcomes by heart valve prosthesis type (mechanical or bioprosthetic) 
Pregnancy outcome Mechanical 
valve 
N=14 
n (%) 
Bioprosthetic 
valve 
N=38 
n (%) 
 
RR (95% CI)* 
Caesarean delivery 10 (71) 16 (42) 1.70 (1.03-2.79) 
Preterm Birth (<37 weeks) 4 (29) 6 (16) 1.81 (0.60-5.47) 
Planned birth† 
   Any planned 
   Planned preterm birth 
 
13 (93) 
  4 (27) 
 
24 (63) 
  4 (11) 
 
1.47 (1.11-1.95) 
2.71 (0.78-9.41) 
SGA infant 3 (21) 6 (16) 1.38 (0.39-4.70) 
Perinatal death 0 (0) 1 (3) not calculated 
Postpartum haemorrhage 4 (36) 7 (18) 1.55 (0.53-4.50) 
ICU admission 2 (14) 3 (8) 1.81 (0.34-9.72) 
Severe maternal morbidity  4 (29) 6 (16) 1.81 (0.60-5.47) 
Maternal major cardiovascular event 2 (14) 3 (8) 1.81 (0.34-9.72) 
* Rate ratio of each outcome among births where the mother had a mechanical heart valve compared 
to those who had a bioprosthetic heart valve 
† Induction of labour or pre-labour caesarean section 
 
